Treatment outcomes and safety of concurrent chemoradiation in older adults with unresectable stage III non-small-cell lung cancer.

ABSTRACT:

Background

Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable stage III non-small-cell lung cancer (NSCLC) and good performance status. However, there is no consensus regarding the treatment of older patients with stage III NSCLC. Therefore, this study aimed to investigate treatment outcomes and safety of CCRT in older patients with unresectable stage III NSCLC compared with those in younger patients.

Methods

We retrospectively examined all patients with unresectable stage III NSCLC treated with CCRT between 2012 and 2023 at four Korean hospitals. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between patients aged ≥70 years (older) and those aged <70 years (younger). We also analyzed d

SUBMITTER: Kim SJ 

PROVIDER: S-EPMC12433024 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature